What Is Semaglutide?
Semaglutide is a long-acting GLP-1 receptor agonist originally developed for type 2 diabetes and later approved in higher doses for chronic weight management. It mimics the naturally occurring hormone glucagon-like peptide-1 (GLP-1), which helps regulate appetite, blood sugar, and gastric emptying. It is one of the best-studied medications in the incretin class.
How It Works
Semaglutide activates GLP-1 receptors throughout the body. In the brain it increases satiety and reduces hunger. In the pancreas it enhances glucose-dependent insulin secretion while reducing glucagon release. It also slows stomach emptying, helping people feel full longer after meals and reducing overall calorie intake.
Potential Benefits Being Studied
Research has demonstrated benefits in chronic weight management, type 2 diabetes, improvement in blood glucose control, reduction of cardiovascular risk in selected populations, improvement in fatty liver disease, and favorable changes in several cardiometabolic risk factors when combined with nutrition and physical activity.
Typical Research and Clinical Dosing
Clinical protocols typically use once-weekly subcutaneous injections with gradual dose escalation over several weeks to minimize gastrointestinal side effects. The exact escalation schedule depends on the formulation and treatment goal.
Administration and Timing
Semaglutide is typically administered subcutaneously into the abdomen, thigh, or upper arm on the same day each week. It may be given with or without food. Rotating injection sites may reduce local irritation.
Possible Side Effects
The most common adverse effects include nausea, vomiting, diarrhea, constipation, abdominal pain, reduced appetite, reflux, and bloating. Less common but more serious concerns include pancreatitis, gallbladder disease, dehydration from prolonged gastrointestinal symptoms, worsening diabetic retinopathy in some individuals, and rare allergic reactions.
Contraindications and Precautions
Individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should discuss potential risks with a qualified healthcare professional. Caution is also appropriate in those with severe gastrointestinal disease or a history of pancreatitis.
Bottom Line
Semaglutide has become a cornerstone of modern metabolic medicine because it addresses appetite regulation and glucose control through the GLP-1 pathway. It has demonstrated substantial benefits for many patients when combined with healthy lifestyle changes, while ongoing research continues to expand our understanding of its long-term effects.
Educational Reminder
This document is intended for educational purposes only and should not replace individualized medical advice.